Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK12 | Q9NYV4 | 7/20 | 0.51 |
| ▸ | CCNK | O75909 | 4/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 16/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 13/20 | 0.49 |
| ▸ | CDK13 | Q14004 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508324 | 0.93 | CSNK1E (0.56) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23508317 | 0.93 | CDK12 (0.57) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23508403 | 0.90 | CSNK1E (0.47) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23508440 | 0.88 | CDK12 (0.49) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23497497 | 0.86 | CSNK1E (0.46) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL30013324 | 0.86 | CSNK1E (0.46) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23508237 | 0.86 | CSNK1E (0.48) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23508470 | 0.86 | CDK12 (0.47) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23508333 | 0.85 | CDK12 (0.36) | CDK12CCNKCSNK1ECSNK1DCDK13 | |
| SCHEMBL23508469 | 0.83 | CSNK1E (0.50) | CDK12CSNK1ECSNK1DCDK13CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | CDK12 132/4885CCNK 87/4885CSNK1E 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.